21:32:54 Europe / Stockholm

Prenumeration

Filter arrow-icon
Språk arrow-icon
2020-10-01 10:13:00
Ny artikel om CombiGene i Biostock
Biostock sammanfattar de senaste nyheterna från CombiGene och pratar med vd Jan Nilsson om betydelsen av de många milstolparna och den fortsatta planen för epilepsiprojektet CG01.https://www.biostock.se/2020/10/combigene-ar-ytterligare-ett-steg-narmare-kliniska-studier/
2020-10-01 10:13:00
New article about CombiGene in Biostock
Biostock summarizes the latest news from CombiGene and talks to CEO Jan Nilsson about the importance of the many milestones and the continued plan for the epilepsy project CG01.https://www.biostock.se/en/combigene-one-step-closer-to-clinical-trials/
2019-05-27 15:00:00
Nytt nummer av CombiGenes nyhetsbrev ute nu
Läs nyhetsbrevet på svenska via länken nedan. https://issuu.com/pub10/docs/combigene_genevagen_2_2019?e=0 Eller ladda ner bilagan
2019-05-27 15:00:00
New issue of CombiGene´s newsletter Ingenious
Read CombiGene´s newsletter Ingeneious in English https://issuu.com/pub10/docs/combigene_ingeneious_2_2019?e=0 Or download the attachment
2019-02-01 14:30:00
New issue of CombiGene´s newsletter Ingenious
Read CombiGene´s newsletter Ingeneious in English https://issuu.com/pub10/docs/combigene_ingeneious__2019?e=0 Or download the attachment
2019-02-01 14:30:00
Nytt nummer av CombiGenes nyhetsbrev ute nu
Läs nyhetsbrevet på svenska via länken nedan. https://issuu.com/pub10/docs/combigene_geneva_gen_1_2019?e=0 Eller ladda ner bilagan
2018-12-17 08:41:41
CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018
Nasdaq Stockholm AB has decided that the shares and subscription warrants (TO2) of CombiGene AB (publ) will be traded on Nasdaq First North Stockholm. The first day of trading is December 19, 2018. The shares and the subscription rights will be traded with unchanged ticker (COMBI) and ISIN-Code (SE0006504593) for the share and (COMBI TO 2) and ISIN-code (SE0011616408) for the subscription rights. ...
2018-12-14 13:40:02
CombiGene featured in an article in Nature, one of the world’s leading scientific journals
The latest number of Nature (Vol. 564, Issue 7735, 13 December 2018) features CombiGene’s operations, and the possibilities of using gene therapy to treat epilepsy. Both CombiGene’s scientific founder, Professor Merab Kokaia, and CEO Jan Nilsson, are quoted. “CombiGene being featured in Nature like this makes me incredibly happy and proud. It is a clear sign that our research and development...
2017-04-18 14:38:59
CombiGene Annual Report 2016
Se årsredovisning >>